WO2015089626A1 - Self-fueled particles for propulsion through flowing aqueous fluids - Google Patents
Self-fueled particles for propulsion through flowing aqueous fluids Download PDFInfo
- Publication number
- WO2015089626A1 WO2015089626A1 PCT/CA2014/000721 CA2014000721W WO2015089626A1 WO 2015089626 A1 WO2015089626 A1 WO 2015089626A1 CA 2014000721 W CA2014000721 W CA 2014000721W WO 2015089626 A1 WO2015089626 A1 WO 2015089626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- particles
- acid
- particle
- average diameter
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 188
- 239000012530 fluid Substances 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 claims abstract description 122
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 37
- 230000000740 bleeding effect Effects 0.000 claims abstract description 30
- 239000002253 acid Substances 0.000 claims abstract description 24
- 150000005323 carbonate salts Chemical class 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 13
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 45
- 108090000190 Thrombin Proteins 0.000 claims description 36
- 229960004072 thrombin Drugs 0.000 claims description 36
- 208000034158 bleeding Diseases 0.000 claims description 29
- 206010053567 Coagulopathies Diseases 0.000 claims description 23
- 230000035602 clotting Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 239000011859 microparticle Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 17
- 150000007524 organic acids Chemical class 0.000 claims description 17
- 238000012384 transportation and delivery Methods 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 230000023555 blood coagulation Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000033001 locomotion Effects 0.000 claims description 7
- 238000011200 topical administration Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000000446 fuel Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- -1 calcium cations Chemical class 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 108010000499 Thromboplastin Proteins 0.000 claims description 2
- 102000002262 Thromboplastin Human genes 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 150000003862 amino acid derivatives Chemical class 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 239000003805 procoagulant Substances 0.000 abstract description 7
- 238000010172 mouse model Methods 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 81
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical class NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960000401 tranexamic acid Drugs 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 239000000504 antifibrinolytic agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
- 229940082620 antifibrinolytics Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 235000015842 Hesperis Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000012633 Iberis amara Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108010066180 tertiary-butyloxycarbonyl-valyl-prolyl-arginyl-7-amino-4-methylcoumarin Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/10—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/10—Inorganic materials
- A61L29/106—Inorganic materials other than carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/18—Carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Definitions
- This invention relates to particles capable of self-propulsion.
- Uncontrolled bleeding occurs in many situations, including severe nosebleeds, postpartum hemorrhage (PPH), trauma, dental procedures, and bleeding in patients with hemophilia.
- PPH postpartum hemorrhage
- the primary concern during severe bleeding is quickly controlling blood loss, although controlling secondary bleeding, infection, and tissue repair is also important.
- Delivery of appropriate therapeutics, such as coagulants, anti-fibrinolytics, antimicrobials, or growth factors to the damaged vasculature can help.
- delivering such agents via systemic injections or via intravascular catheter is often not possible, particularly if the person is far from an advanced clinical setting.
- Topical delivery is limited by the difficult biophysical problem of moving agents upstream through blood flow and deep enough into an area of bleeding where they could treat the leaking vessels. Severe hemorrhaging is often fatal because coagulants are not able to reach and clot blood at the level of damaged vessels.
- Propelled particle systems have been previously proposed for drug delivery. 1"6 Some of these particles rely on gas generation and bubble propulsion to create their velocity. Such particles may contain metal catalysts that convert hydrogen peroxide dissolved in aqueous solution to oxygen gas. Other examples convert hydrogen ions in strongly acidic solutions (pH ⁇ 1) to a hydrogen gas. Thus, the "fuel” for propulsion or a necessary reactant is placed in the environment of the particle and is not present in the particle itself. Mechanisms such as ultrasound or magnetically-driven swimmers for propulsion have also been proposed.
- 7,8 Particles that employ gas/bubble propulsion have not been used in vivo because they rely on having a "fuel” (e.g., hydrogen peroxide) which is toxic or a required reactant (i.e., a strong acid) dispersed in the living environment. Also, they generally propel at velocities many orders of magnitude slower than blood flow. 1 ' 4
- a fuel e.g., hydrogen peroxide
- a required reactant i.e., a strong acid
- microparticles are known for use in carrying biologically active substances to enhance delivery to target cells, tissues, etc.
- Microparticles including porous versions thereof that are made of polyelectrolytes and are capable of adsorption of biologically active materials have, been developed for drug delivery. Examples of such particles have been made by crystallizing inorganic salts such as calcium carbonate.
- processes for controlled fabrication of films and particles have been developed, including ones which allow for precise control of film or particle shell thickness (i.e., nanoporous template-assisted layer-by-layer (ELbL) protocols).
- EbL nanoporous template-assisted layer-by-layer
- Volodkin et al. 9 describe production of porous CaC0 3 (vaterite) particles with a size distribution from 4 to 6 ⁇ that encapsulate proteins that are adsorbed to the particles. Such particles were found to be biocompatible and decomposable at neutral pH.
- compositions comprising metal carbonates and organic acids that effervesce in contact with aqueous media have been disclosed as additives for collection devices containing bodily fluids (U.S. Patent No. 6225123).
- the latter Patent teaches that such compositions may include a clot activator such as silica particles. The effervescence will assist in distributing the clot activator throughout a collection vessel to promote rapid blood coagulation prior to removal of serum.
- Such additives can be made in solid forms (including tablets) for addition to tubes containing blood samples.
- Foaming hemostatic and adhesive fibrin preparations that may contain calcium ions are also known, such as those disclosed in WO2000/038752 and WO2011/123346.
- Spreading of components that provide for a fibrin matrix results from the foaming action.
- the foaming results from generation of C0 2 .
- Neither reference discloses particles that propel themselves.
- WO2011/123346 discloses the generation of C0 2 by mixing a solution containing fibrin scaffold components and sodium bicarbonate with an acidic solution.
- WO2000/038752 discloses a composition in powder or granular form that contains components for forming a fibrin matrix, together with a carbonate and a physiologically acceptable organic acid. The latter composition effervesces upon contacting moisture.
- the present disclosure is of a simple, self-propelling particle system that can deliver a cargo through flowing aqueous solutions.
- This system is functional, and in a mouse model of severe hemorrhage the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.
- This system has application for the delivery of cargo through flowing aqueous fluids.
- the fluid will be flowing at a rate of less than about 5, 4, 3, 2, or 1 mm/s.
- Compositions of this invention may be useful for delivery of therapeutics to sites of injury or hemorrhage or in treating external bleeding that originates from inside the body, such as the uterus, naval cavity, or abdominal cavity, where traditional topical agents are not particularly effective.
- This disclosure is based at least in part, on the discovery that self-fueled particles can generate sufficient energy to propel themselves against the flow of a moving fluid, including flowing blood.
- Such particles may be used for local delivery of biologically active agents including delivery which allows for movement of the particles into areas of bleeding.
- the particles themselves may be designed to assist in blood clotting and/or wound healing.
- This disclosure relates to a method of conveying a cargo molecule or cargo particle through an aqueous fluid, the method comprising providing a self-fueled particle associated with said cargo molecule or particle, the self-fueled particle comprising a fuel for releasing gas to propel the particle when contacted with the aqueous fluid.
- the particles may be formed of a carbonate salt as described herein.
- compositions comprising solid particles that comprise a carbonate salt; and, an acid, in solid form, in admixture or distributed in or on a non-aqueous matrix, support or carrier.
- a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ⁇ or less; and (ii) an acid in solid form.
- the composition consists essentially of the acid in solid form and the particles formed of a carbonate salt, with or without an associated cargo.
- the carbonate salt containing particles may be associated with a cargo particle or a cargo molecule, which may be a biologically active agent.
- this invention also relates to a method of conveying a cargo molecule or particle through a flowing aqueous fluid using such a composition that is introduced into the fluid.
- the fluid may be a bodily fluid.
- compositions as described herein for delivery of a biological agent through a bodily fluid.
- the bodily fluid may be flowing.
- Such use may be for treatment of bleeding.
- a composition as described herein may be for administration locally, including to an area of bleeding.
- a composition as described herein may be adapted for topical administration or placement directly on an area bleeding during surgical treatment.
- This disclosure also relates to CaC0 3 nanoparticles and/or micropar icles that are associated with a biological agent capable of affecting clotting, including agents that promote clotting such as thrombin, tissue factor and other procoagulants or anti-fibrinolytics.
- the agent may be one that diminishes clots or clotting such as tissue plasminogen activator (tP A).
- tP A tissue plasminogen activator
- This disclosure also relates to non-aqueous compositions comprising CaC0 3 nanoparticles and/or microparticles and the organic acid THX-NH 3 + .
- the particles may be associated with a cargo molecule or particle as described herein.
- the composition may consist essentially of the acid and the particles, with or without associated cargo.
- CaC0 3 particles for use in this invention may be microparticles of a size ranging from about 1 to about 100 ⁇ in average diameter; less than about 50 ⁇ in average diameter; about 20 to about 60 ⁇ in average diameter; 2 to about 10 ⁇ in average diameter; or about 4 to 6 or about 10 um in average diameter. Nanoparticles having a diameter of less than about 1 ⁇ (e.g. about 0.1 to about 0.5 ⁇ or greater) are also contemplated.
- the particles may be porous. Pore size in the particles may be in the range of about 10 to about 100 nm, or about 20 to about 60 nm. Such particles may be ones prepared by precipitation of porous vaterite particles from an equimolar solution of Na 2 C0 3 and CaCl 2 .
- compositions of this invention may be distributed on or impregnated in materials such as gauze, wound dressings, sponges, nasal packing material, and balloons used in surgical treatment.
- a balloon may be a uterine application.
- delivery devices including syringes and catheters comprising a composition as described herein and may include other devices such as pumps, distribution apparatus, tubing or the like, not necessarily intended for treatment of a living organism.
- Compositions of this invention may be employed in microfluidic systems.
- Figure 1A is a schematic showing CaC0 3 microparticles associated with a cargo that propel themselves through aqueous solutions when combined with an organic acid. The 3- component system reacts and C0 2 is released from the microparticles when placed in water.
- Figure IB is an image of immobilized CaC0 3 microparticles (10 ⁇ dia.) associated with a fluorescently-tagged cargo molecule, FITC-dextran. Scale bar is 30 ⁇ .
- Figure 1C is a schematic showing how particle propulsion was measured for the results shown in Figures ID and IE.
- Figures ID and IE are images of fluorescently-tagged particles appearing at the surface of a buffered solution (D) and blood (E), after propelling from 16 mm below the surface. Scale bar is 2 mm.
- Figure 2A is a series of images showing CaC0 3 particles propelling upstream through a flowing acidic solution over time.
- the circled particle had vertical and horizontal velocity components of 66 mm/s and 3 mm s, respectively.
- Figure 2B is a graph showing that particle velocity increases with the volume of bubbles to which the particle is attached.
- Figure 2C is an image showing particles carried upward by C0 2 bubbles. Scale bars are 2 mm.
- Figure 2D is a schematic showing how propulsion through flowing solutions was measured. Particles were applied at the bottom of a tube and the movement of particles upstream though flowing water was quantified.
- Figure 2E is a graph showing that the amount of particles that propelled upstream decreased at higher flow rates. The inset shows the fraction of particles that accumulated for each flow velocity at 20 s.
- Figure 3 A is a graph showing amounts of thrombin adsorbed inside and outside of
- FIG. 3B is a schematic showing how clot time of non-flowing plasma was measured. Thrombin in a buffered solution or associated with CaC0 3 particles was placed near the top of a tube of non-flowing blood plasma. CaC0 3 particles were mixed with either protonated or unprotonated tranexamic acid, yielding propelling or non-propelling mixtures respectively.
- Figure 3C is a graph showing clot initiation times at the tops and bottoms of tubes.
- Figure 3D is a schematic of clotting and occlusion of flowing blood plasma, showing flow rate of plasma being measured after particles were applied at the bottom of a tube.
- 3E is a graph showing clotting of plasma at various flow rates by thrombin-loaded particles.
- Figure 4A is a perspective view of a mouse used in a model for severe hemorrhage. A terminal 8 mm portion of the mouse tail was amputated.
- Figure 4B is a graph showing total bleeding times following application of propelled and non-propelled thrombin associated particles at the site of amputation. Mice were observed for 10 min following amputation. *p
- Figure 5 is a graph showing volumes of blood lost from mice after their livers were punctured. * P ⁇ 0.05, **P ⁇ 0.01. Error bars indicate S.E.M. DETAILED DESCRIPTION OF THE INVENTION
- compositions of this invention comprise a carbonate salt and an acid and are therefore moisture sensitive.
- the composition should be prepared such that there is minimal opportunity for reaction of the carbonate salt and the acid until the composition is contacted with an aqueous medium.
- the salts may be physiologically acceptable salts. Examples of carbonate salts that are physiologically acceptable include CaC0 3 and Na 2 C0 3 . However, in applications where wound healing is enhanced and particularly in cases where the composition is employed to enhance blood clotting, the preferred salt is CaC0 3 .
- the particles may be prepared by any means but in some cases, it can be advantageous to prepare porous particles to increase particle surface area and/or to provide for at least partial encapsulation of a cargo molecule or particle. Methods for producing porous carbonate salt particles are known in the art, such as in the above-described publication of Volodkin et al. 9
- the acid component a composition of this invention may be any acid suitable for preparation of the composition in solid form and/or for the intended use of the composition.
- the acid may be physiologically acceptable for use in biological systems.
- suitable acids include organic acids.
- physiologically acceptable organic acids include citric acid and malic acid.
- Amino acids and organic acids derived from amino acids that are not chelators at physiological pH are suitable. These include amino acids that are protonated at physiological pH (e.g., glycine) or which can be protonated in that pH (e.g., tranexamic acid).
- an organic acid derived from an amino acid that enhances blood clotting is aminocaproic acid.
- anti-fibrinolytic agents such as tranexamic acid or aminocaproic acid or procoagulants should be avoided.
- Cargo particles or molecules that may be associated with the carbonate salt particles for use in this invention may be any substance that can be so associated.
- the cargo may be present to act as a label or the cargo may have another function such as a biological function.
- the term “associated” is meant to include any form of binding, including electrostatic interaction. Polyelectrolytes such as CaC0 3 particles are particularly suitable for adsorbing biological material such as proteins, nucleic acids, polysaccharides and other charged substances such as dextrans.
- the term “associated” is also intended to include physical constraints such as encapsulating or otherwise enclosing an associated substance.
- Cargo particles to be associated with the carbonate salt particles for use in this invention should be of a size approximately similar to the carbonate salt particle or smaller. Thus, in particular embodiments, it is desirable for a cargo particle to be 10 ⁇ or 5 ⁇ or less in size.
- Biologically active agents that may be associated as cargo molecules with carbonate salt particles in this invention may be any active macromolecule (such as a protein) or a small molecule that can be so associated and may include, without limitation: growth factors; antimicrobials; antibiotics; styptics; anesthetics; anti-proliferative drugs such as methotrexate and other anti-cancer drugs; procoagulants such as thrombin; anti-fibrinolytic agents; fibrinolytic agents such as urokinase-type plasminogen activator (uPA); antifibrotics such as acetylsalicylic acid (ASA); and anti-inflammatory agents such as dexamethasone.
- active macromolecule such as a protein
- small molecule that can be so associated and may include, without limitation: growth factors; antimicrobials; antibiotics; styptics; anesthetics; anti-proliferative drugs such as methotrexate and other anti-cancer drugs; procoagulants such as thrombin;
- Carbonate salt particles employed in the invention may be of a size which is not desirable for systemic delivery nor would systemic delivery be recommended if a particular composition of this invention comprises a procoagulant. Nevertheless, compositions of this invention can be suitable for direct application to an area to be treated. Such application includes local administration, topical administration, placement of a composition of this invention on an area during surgical treatment, and the like. Local administration may comprise delivery of a composition of this invention by means of a device such as a catheter to a particular target area. Topical administration may comprise placement of a composition of this invention directly on a wound or area of bleeding. Compositions comprising nonparticles may be useful for systemic administration.
- compositions of this invention may be for use in propelling a cargo through an aqueous fluid that is in motion in virtually any system, including biological systems.
- Compositions of this invention may be formulated for therapeutic use using known techniques and materials such as is described in texts such as Remington: The Science and Practice of Pharmacy (latest edition).
- a composition of the present invention may be formulated into therapeutic compositions with appropriate pharmaceutically acceptable carriers or diluents. Preparations may be solid or non-aqueous, semi-solid and liquid forms, such as tablets, capsules, pills, powders, granules, dragees, gels, creams, slurries, ointments, and suspensions.
- compositions of this invention may be present on microcarriers known in the art, including physical microstructures that have been previously employed as self-propelling particles. These include tubular structures, including ones with open ends as well as ones in conical shape having open ends of different diameters. Such microcarriers may also be in the form of a bead, microcapsule, etc. They may be comprised of materials such as glass, metal and/or polymers and may be magnetic and/or labelled. Degradable polymer microspheres are known for use with therapeutic proteins.
- Microspheres can be prepared from degradable polymers such as poly(lactide-co-glycolide) (PLG), polyanhydrides, poly (ortho esters), nonbiodegradable ethylvinyl acetate polymers, in which proteins are entrapped in the polymer (e.g., see: Ranade and Hollinger, "Drug Delivery Systems” (CRC Press 1996).
- degradable polymers such as poly(lactide-co-glycolide) (PLG), polyanhydrides, poly (ortho esters), nonbiodegradable ethylvinyl acetate polymers, in which proteins are entrapped in the polymer (e.g., see: Ranade and Hollinger, "Drug Delivery Systems” (CRC Press 1996).
- compositions of this invention may be associated with another material that has a desirable biological effect, including materials that affect clotting.
- compositions of this invention may contain or be associated with silica or kaolin based compositions as currently employed for control of hemorrhaging.
- compositions of this invention may be distributed on or within various materials that are employed for therapeutic purposes, including gauze, packing, balloons, etc.
- Various means may be used for adhering or impregnating a composition of this invention to such materials.
- such material present in the form of sheets or layers may separately contain the carbonate salt and acid components of a composition of this invention, to assist localization of the components and to minimize reaction prior to application to an area where the material will be wetted by a bodily fluid.
- compositions of this invention and materials comprising such compositions are typically dry but may also be present in a non-aqueous gel or a liquid such as an oil.
- a non-aqueous gel or a liquid such as an oil.
- Preparation of non-aqueous carriers for therapeutic purposes which employ hydrophilic polymers is known in the art.
- non-aqueous gels for topical delivery of moisture- sensitive drugs are known 14 .
- kits comprising the carbonate salt and acid components of a composition as defined above, which components are present in separate containers or packaging. Such a kit may include instructions for use of the components for preparation and use of a composition of this invention.
- Delivery devices may comprise a composition of this invention. Such devices may be for use in therapeutic administration of a composition of this invention and can include catheter containing apparatus suitable for delivery of a biological agent such as tPA locally to a target area.
- a biological agent such as tPA
- CaC0 3 Calcium carbonate
- Porous microparticles used in this example can be prepared by precipitation of CaC0 3 when Na 2 C0 3 is added to a solution containing CaCl 2 , based on the procedure described by Volodkin et al. 9
- ice cold 0.33 M Na 2 C0 3 can be added to an equal volume of ice cold 0.33 M CaCl 2 with rapid mixing.
- the particles can be fluorescently labeled, for example by precipitating the CaC0 3 in the presence of 0.1 mg/mL FITC-dextran (4 KDa mw) or with fluorescent polystyrene micro or nanoparticles (such as green-fluorescent microspheres available from Polysciences, Inc. or dark red-fluorescent carboxylate-modified polystyrene nanoparticles available from Life Technologies).
- Precipitated CaC0 3 particles can be purified by centrifugation, washed with deionized water, and dried (for example at 60° C). Such particles will generally have spherical geometry and may typically have diameters ranging from about 2 to about 10 ⁇ (Fig. IB). We found that when such CaC0 3 microparticles were mixed with a solid organic acid, they were rapidly propelled though both buffered aqueous solutions and whole blood (Fig. 1A).
- TXA tranexamic acid
- TXA-NH 3 + doubly-protonated form
- 6 M HC1 was added to 0.5 M neutrally-charged TXA (TXA-NH 2 ) until pH 4.3.
- the acidified solution was lyophilized yielding solid TXA-NH 3 + .
- CaC0 3 microparticles were mixed at approximately 1 : 1 molar ratio with TXA-NH 3 + and injected directly to phosphate-buffered saline (PBS) or whole blood, 16mm below the surface via a needle (Fig. lC). The particles reacted vigorously, rising and spreading at the surface within seconds (Fig. ID). After the reaction, the pH of the solution was neutral, as the acid was neutralized when C0 3 2" protonated and reacted.
- PBS phosphate-buffered saline
- Fig. ID phosphate-buffered saline
- the flow velocity of blood varies widely between different sized blood vessels and different types of wounds. In capillaries the flow velocity is approximately 1 mm s, whereas in arteries with diameters of several millimeters, such as coronary arteries, the velocity is between 10 and 100 mm/s. 10
- the CaC0 3 particles described above were capable of a velocity of 3 mm/s. While such a velocity would be insufficient to move against the flow of blood within an artery, such particles are capable of propulsion through blood flow in wounds and capillary beds.
- intravascular catheters can sometimes be used to deliver agents to the vasculature feeding damaged vessels, and this approach is used to deliver embolic agents to halt blood flow.
- treating severe bleeding from vessels that cannot be targeted with catheters, or when immediate treatment is necessary requires more traditional approaches, such as topical compression.
- Compressing or packing materials into the area of bleeding is the standard treatment.
- Many technologies and materials have been developed for this purpose, such as gelatin foams, modified cellulose and other functionalized dressings, and powders composed of zeolites. Thrombin can also be applied topically in solution.
- none of these methods are highly effective during severe bleeding or when external blood loss originates from inside a cavity of the body.
- thrombin a serine protease that activates the coagulation system and directly cleaves fibrinogen
- the carbonate microparticles were suspended at 10% w/v in 447 ⁇ bovine thrombin (Thr) in lOmM HEPES and incubated at 4° for Ali.
- the particles were purified by centrifugafion (5 min at 10,000g) to remove excess liquid, and were dried by lyophilization.
- porous CaC0 3 particles associated with the fibrolytic agent, uPA was also made.
- thrombin substrate Boc-Val-Pro-Arg-MCA, Peptide Institute Inc.
- thrombin cleavage of which by thrombin yields a blue fluorescent product detectable by spectrophotometry.
- thrombin-calcium carbonate (Thr-CaC0 3 ) particles were solubilized in lOOmM HC1 prior to addition of fluorescent substrate.
- HBS HEPES-buffered saline
- Thr-CaC0 3 was mixed at a 1 :1 mass ratio with TXA-N3 ⁇ 4 + to yield a propelling particle mixture.
- a non-propelling mixture consisted of a 1:1 ratio of Thr-CaCOs with lyophilized TXA-N3 ⁇ 4. The ability of the two mixtures to initiate clotting in platelet-poor blood plasma was measured and compared against addition of a similar amount of thrombin (approximately 1 pmol) in HEPES buffer and a control receiving no treatment.
- CaC0 3 particles propel upward at a greater velocity than in a lateral direction.
- the ability of particles to clot both at the site of application and below the site was assessed by injecting particles near the to of a column of plasma that was 25 mm tall. Initiation of clotting was measured both at the top and the bottom of the column by monitoring the formation of fibrin.
- the blood plasma was laced with green-fluorescent beads in order to monitor movement and formation of solid fibrin mesh and clot initiation. Clotting at the top was measured visually, and when the plasma became opaque or appeared gelled, clotting was confirmed by gentle manipulation with a micropipette.
- the thrombin solution caused no acceleration of clot initiation at the bottom compared to the control. Clotting took about 30 min, as the clot needed to propagate down through the column by diffusion. Clotting at the bottom was faster using non-propelled particles, occurring in 3.7 min as compared to 10 min for the propelled particles. However, this enhanced downward clotting rate was due to the unreacted thrombin-loaded CaC0 3 particles sinking to the bottom. Most propelled particles reacted and produced gas at the top so only a fraction of the particles sank to the bottom yielding a slightly slower clot time compared to non-propelling particles. Although the propelled particles out-performed the thrombin solution in this assay, a particular advantage for the propelling particles would come from an ability to propel though flowing solutions.
- thrombin particles were applied to the bottom of plasma flowing through a glass capillary tube (Fig. 3D,E).
- a microfluidic system was used to control the flow of plasma, and monitor the flow to determine when clotting occluded flow in the capillary tube.
- the background occlusion times in the system were approximately 30 min.
- occlusion also occurred at approximately 30 min.
- the thrombin alone occluded at very slow velocities of up to 0.06 mm/s, and showed no difference from controls at 0.6 mm/s.
- the non- propelled thrombin was able to form a clot at the exit of the tubing, but only at low flows was this clot able to persist and propagate up the tubing. At high flows, the clot was easily pushed out and the flow of plasma resumed. The propelled thrombin initiated clotting and occluded flow at velocities much higher than non-propelled thrombin. The particles propelled upwards, against flow, and accumulated high within the tubing. Clotting was seen to initiate at regions with the highest concentration of particles. At a flow velocity of 3 mm/s, the time of occlusion was still considerably faster than the non-propelled mixture or controls. This shows that the self-propelling particles loaded with thrombin would be effective at clotting flowing plasma by initiating clotting upstream of the site of application.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Geology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/105,553 US10238598B2 (en) | 2013-12-16 | 2014-10-02 | Self-fueled particles for propulsion through flowing aqueous fluids |
CA2937049A CA2937049C (en) | 2013-12-16 | 2014-10-02 | Self-fueled particles for propulsion through flowing aqueous fluids |
EP14871728.3A EP3082866B1 (en) | 2013-12-16 | 2014-10-02 | Self-fueled particles for propulsion through flowing aqueous fluids |
US16/295,819 US11266596B2 (en) | 2013-12-16 | 2019-03-07 | Self-fueled particles for propulsion through flowing aqueous fluids |
US17/687,364 US20220233432A1 (en) | 2013-12-16 | 2022-03-04 | Self-fueled particles for propulsion through flowing aqueous fluids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361916674P | 2013-12-16 | 2013-12-16 | |
US61/916,674 | 2013-12-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/105,553 A-371-Of-International US10238598B2 (en) | 2013-12-16 | 2014-10-02 | Self-fueled particles for propulsion through flowing aqueous fluids |
US16/295,819 Division US11266596B2 (en) | 2013-12-16 | 2019-03-07 | Self-fueled particles for propulsion through flowing aqueous fluids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015089626A1 true WO2015089626A1 (en) | 2015-06-25 |
Family
ID=53401839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2014/000721 WO2015089626A1 (en) | 2013-12-16 | 2014-10-02 | Self-fueled particles for propulsion through flowing aqueous fluids |
Country Status (4)
Country | Link |
---|---|
US (3) | US10238598B2 (en) |
EP (1) | EP3082866B1 (en) |
CA (1) | CA2937049C (en) |
WO (1) | WO2015089626A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109529094A (en) * | 2018-11-05 | 2019-03-29 | 首都师范大学 | A kind of efficient hemostatic material and preparation method thereof can promote wound healing |
EP3349766A4 (en) * | 2015-09-20 | 2019-05-01 | Ariel-University Research and Development Company Ltd. | Anti-hemorrhaging compositions |
WO2019105519A1 (en) * | 2017-12-03 | 2019-06-06 | Abd Elaal Nasser Kamal | Tranexamic acid coated or eluted uterine balloon and co-attached cervical shutter in the management of postpartum haemorrhage |
US11266596B2 (en) | 2013-12-16 | 2022-03-08 | The University Of British Columbia | Self-fueled particles for propulsion through flowing aqueous fluids |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470309B (en) * | 2022-03-04 | 2022-11-29 | 西南大学 | Directional driving hemostasis microsphere with puncture function and preparation method thereof |
CN115212344B (en) * | 2022-08-01 | 2023-08-22 | 西南大学 | Self-expansion hemostatic aerogel and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038752A1 (en) | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
US6225123B1 (en) | 1997-04-30 | 2001-05-01 | Becton Dickinson And Company | Additive preparation and method of use thereof |
CA2449436A1 (en) * | 2001-06-22 | 2003-01-03 | Millard Marsden Mershon | Compositions and methods for reducing blood and fluid loss from open wounds |
CA2599929A1 (en) * | 2006-09-06 | 2008-03-06 | Tyco Healthcare Group Lp | Bioactive substance in a barbed suture |
US20110066182A1 (en) * | 2009-04-07 | 2011-03-17 | Biomedica Management Corp | Tissue Sealant for Use in Non Compressible Hemorrhage |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB883169A (en) * | 1958-09-05 | 1961-11-22 | Henry Brout | Dry effervescent concentrate |
US3939289A (en) * | 1973-04-02 | 1976-02-17 | General Foods Corporation | Dry carbonation source for a beverage concentrate and method of preparing the same |
JPS56158707A (en) | 1980-04-08 | 1981-12-07 | Lion Corp | Composition for oral use |
US5209251A (en) | 1988-03-29 | 1993-05-11 | Colgate-Palmolive Company | Dental floss |
US5951531A (en) | 1993-04-20 | 1999-09-14 | Medchem Products, Inc. | Apparatus and method for applying a particulate hemostatic agent to living tissue |
IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
US5779464A (en) * | 1996-01-10 | 1998-07-14 | The Ohio State University Research Foundation | Calcium carbonate sorbent and methods of making and using same |
US6534016B1 (en) * | 1997-04-30 | 2003-03-18 | Richmond Cohen | Additive preparation and method of use thereof |
IT1292410B1 (en) | 1997-06-24 | 1999-02-08 | Roberto Beretta | READY-TO-USE CONTAINER TO OBTAIN AUTOLOGOUS FIBRIN GLUE |
DE19837073A1 (en) | 1998-08-17 | 2000-03-23 | Lohmann Therapie Syst Lts | Foil-shaped drug carriers |
JP3484425B2 (en) | 2001-03-14 | 2004-01-06 | 花王株式会社 | Toothpaste |
DE10224607B4 (en) | 2002-06-04 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Film-form, disintegratable preparations for drug release and process for their preparation |
US7090868B2 (en) * | 2002-09-13 | 2006-08-15 | University Of Florida | Materials and methods for drug delivery and uptake |
JP3894110B2 (en) | 2002-11-29 | 2007-03-14 | ライオン株式会社 | Whitening dentifrice composition |
US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
WO2007002013A2 (en) | 2005-06-20 | 2007-01-04 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
DE102006037362B3 (en) | 2006-08-09 | 2007-09-20 | Heraeus Kulzer Gmbh | Bone-replacement material has calcium carbonate, which is suspended as particulate calcium carbonate in aqueous solution, which contains water soluble haemostatic agent |
US9289196B2 (en) * | 2006-12-12 | 2016-03-22 | Cook Medical Technologies Llc | Hemostatic substance with a coating |
TWI395595B (en) * | 2009-04-01 | 2013-05-11 | Colgate Palmolive Co | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof |
CN102724968A (en) * | 2010-01-08 | 2012-10-10 | 普罗菲布瑞克斯公司 | Dry powder fibrin sealant |
US20120004636A1 (en) * | 2010-07-02 | 2012-01-05 | Denny Lo | Hemostatic fibrous material |
RU2552348C2 (en) * | 2010-10-27 | 2015-06-10 | Колгейт-Палмолив Компани | Composition for oral cavity care, containing arginine and calcium carbonate |
JP5669152B2 (en) * | 2011-03-30 | 2015-02-12 | 国立大学法人 名古屋工業大学 | Skeleton nanoparticles and method for producing the same |
RU2013155713A (en) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | COMPOSITIONS FOR TREATMENT OF THE RAS |
EP2695605B1 (en) * | 2012-08-07 | 2017-05-03 | Parapharm Development Ltd. | Tranexamic acid composition |
EP2719373B1 (en) * | 2012-10-12 | 2017-04-19 | Omya International AG | Fast disintegrating solid dosage form formulation comprising functionalized calcium carbonate and method of their manufacture |
EP3082866B1 (en) | 2013-12-16 | 2024-08-14 | The University Of British Columbia | Self-fueled particles for propulsion through flowing aqueous fluids |
KR20180014778A (en) | 2015-06-03 | 2018-02-09 | 트리아스텍 인코포레이티드 | Formulations and uses thereof |
CA3023278C (en) | 2016-05-05 | 2019-04-30 | Triastek, Inc. | Controlled release dosage form |
-
2014
- 2014-10-02 EP EP14871728.3A patent/EP3082866B1/en active Active
- 2014-10-02 US US15/105,553 patent/US10238598B2/en active Active
- 2014-10-02 CA CA2937049A patent/CA2937049C/en active Active
- 2014-10-02 WO PCT/CA2014/000721 patent/WO2015089626A1/en active Application Filing
-
2019
- 2019-03-07 US US16/295,819 patent/US11266596B2/en active Active
-
2022
- 2022-03-04 US US17/687,364 patent/US20220233432A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6225123B1 (en) | 1997-04-30 | 2001-05-01 | Becton Dickinson And Company | Additive preparation and method of use thereof |
WO2000038752A1 (en) | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
CA2363916A1 (en) * | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
CA2449436A1 (en) * | 2001-06-22 | 2003-01-03 | Millard Marsden Mershon | Compositions and methods for reducing blood and fluid loss from open wounds |
CA2599929A1 (en) * | 2006-09-06 | 2008-03-06 | Tyco Healthcare Group Lp | Bioactive substance in a barbed suture |
US20110066182A1 (en) * | 2009-04-07 | 2011-03-17 | Biomedica Management Corp | Tissue Sealant for Use in Non Compressible Hemorrhage |
WO2011123346A1 (en) | 2010-03-30 | 2011-10-06 | Falus George D | Tissue sealant for use in non compressible hemorrhage |
Non-Patent Citations (16)
Title |
---|
CHOW, K. T. ET AL.: "Formulation of Hydrophilic Non-Aqueous Gel: Drug Stability in Different Solvents and Rheological Behavior of Gel Matrices", PHARMACEUTICAL RESEARCH, vol. 25, no. 1, 2008, pages 207 - 217, XP019579485 |
DREYFUS, R. ET AL.: "Microscopic artificial swimmers", NATURE, vol. 437, 2005, pages 862 - 865 |
GAO, W. ET AL.: "Hydrogen-Bubble-Propelled Zinc-Based Microrockets in Strongly Acidic Media", J. AM. CHEM. SOC., vol. 134, 2012, pages 897 - 900 |
GARCIA-GRADILLA, V. ET AL.: "Functionalized ultrasound-propelled magnetically guided nanomotors: toward practical biomedical applications", ACS NANO, vol. 7, 2013, pages 9232 - 9240, XP055766858, DOI: 10.1021/nn403851v |
ISMAGILOV, R. F.SCHWARTZ, A.BOWDEN, N.WHITESIDES, G. M: "Autonomous movement and self-assembly", ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 41, 2002, pages 652 - 654 |
KAWAI, K. ET AL.: "Calcium-Based Nanoparticles Accelerate Skin Wound Healing", PLOS ONE, vol. 6, no. 11, 2011, pages e27106 |
KOZEN, B. G.KIRCHER, S. J.HENAO, J.GODINEZ, F. S.JOHNSON, A. S: "An alternative hemostatic dressing: Comparison of CELOX, HemCon, and QuikClot", ACADEMIC EMERGENCY MEDICINE, vol. 15, 2008, pages 74 - 8 |
KURALAY, F. ET AL.: "Self-Propelled Carbohydrate-Sensitive Microtransporters with Built-in Boronic Acid Recognition for Isolating Sugars and Cells", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, 2012, pages 15217 - 15220 |
PATRA, D. ET AL.: "Intelligent, self-powered, drug delivery systems", NANOSCALE, vol. 5, pages 1273 - 1283 |
PAXTON, W. F.SUNDARARAJAN, S.MALLOUK, T. E.SEN, A: "Chemical locomotion", ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 45, 2006, pages 5420 - 5429 |
RANADEHOLLINGER: "Remington: The Science and Practice of Pharmacy", 1996, CRC PRESS |
See also references of EP3082866A4 |
VENNEMANN, P.LINDKEN, R.WESTERWEEL, J: "In vivo whole-field blood velocity measurement techniques", EXPERIMENTS IN FLUIDS, vol. 42, 2007, pages 495 - 511, XP019515744, DOI: 10.1007/s00348-007-0276-4 |
VOLODKIN, D. V.LARIONOVA, N. I.SUKHORUKOV, G. B: "Protein encapsulation via porous CaC03 microparticles templating", BIOMACROMOLECULES, vol. 5, 2004, pages 1962 - 1972, XP055018196, DOI: 10.1021/bm049669e |
WU, Z. ET AL.: "Self-Propelled Polymer-Based Multilayer Nanorockets for Transportation and Drug Release", ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 52, 2013, pages 7000 - 7003 |
ZHAO, G.VIEHRIG, M.PUMERA, M: "Challenges of the movement of catalytic micromotors in blood", LAB ON A CHIP, vol. 13, 2013, pages 1930 - 1936 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11266596B2 (en) | 2013-12-16 | 2022-03-08 | The University Of British Columbia | Self-fueled particles for propulsion through flowing aqueous fluids |
EP3349766A4 (en) * | 2015-09-20 | 2019-05-01 | Ariel-University Research and Development Company Ltd. | Anti-hemorrhaging compositions |
US10695364B2 (en) | 2015-09-20 | 2020-06-30 | Ariel-University Research And Development Company Ltd. | Anti-hemorrhaging compositions |
WO2019105519A1 (en) * | 2017-12-03 | 2019-06-06 | Abd Elaal Nasser Kamal | Tranexamic acid coated or eluted uterine balloon and co-attached cervical shutter in the management of postpartum haemorrhage |
US11717325B2 (en) | 2017-12-03 | 2023-08-08 | Nasser Kamal Abd Elaal | Medicated uterine balloon with cervical barricade for management of postpartum hemorrhage |
CN109529094A (en) * | 2018-11-05 | 2019-03-29 | 首都师范大学 | A kind of efficient hemostatic material and preparation method thereof can promote wound healing |
Also Published As
Publication number | Publication date |
---|---|
EP3082866A1 (en) | 2016-10-26 |
EP3082866A4 (en) | 2017-06-14 |
EP3082866B1 (en) | 2024-08-14 |
US11266596B2 (en) | 2022-03-08 |
US10238598B2 (en) | 2019-03-26 |
CA2937049A1 (en) | 2015-06-25 |
US20160317434A1 (en) | 2016-11-03 |
US20190201325A1 (en) | 2019-07-04 |
US20220233432A1 (en) | 2022-07-28 |
CA2937049C (en) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11266596B2 (en) | Self-fueled particles for propulsion through flowing aqueous fluids | |
Balmayor et al. | Controlled delivery systems: from pharmaceuticals to cells and genes | |
TWI548417B (en) | Hemostatic compositions | |
EP2748299B1 (en) | Targeting microbubbles | |
US20180036338A1 (en) | Flowable hemostatic composition | |
Lin et al. | Recent advances in CO2 bubble-generating carrier systems for localized controlled release | |
MX2007013914A (en) | Compositions and methods using microspheres and non-ionic contrast agents. | |
AU2016367536B2 (en) | Thrombin microcapsules | |
KR20070117589A (en) | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers | |
Shi et al. | Targeted delivery of hemostats to complex bleeding wounds with magnetic guidance for instant hemostasis | |
WO2009105231A1 (en) | Compositions and methods for treating vascular disorders | |
Li et al. | Magnetic field-mediated Janus particles with sustained driving capability for severe bleeding control in perforating and inflected wounds | |
US9289196B2 (en) | Hemostatic substance with a coating | |
CN101229389A (en) | Method of preparing nanometer fossilization stanching material | |
Ren et al. | Preparation and application of hemostatic microspheres containing biological macromolecules and others | |
CN111420114A (en) | Self-pushing type hemostatic gauze/dressing | |
CN109432057A (en) | A kind of stomach is interior to position site-specific drug delivery mini-pill and preparation method thereof | |
CN2920163Y (en) | Nanometer hemostatic plaster | |
CN111035799A (en) | Self-propelled particle for obtaining self-propelled foaming tissue sealant and preparation method thereof | |
CN103585645A (en) | Three-dimensional (3D)-printing-based biocompatible ultrasonic contrast agent and preparation method thereof | |
Qin et al. | Recent advancements in Mg-based micromotors for biomedical and environmental applications | |
CN105214145A (en) | The application of polylactic acid microsphere in hemorrhage | |
Wang et al. | 15 Hydrogels for Drug Delivery | |
Qiu et al. | Magnetic-navigable silk fibroin microneedles for oral drug delivery: Ensuring long-lasting helicobacter pylori eradication and rapid hemostasis in the stomach | |
WO2005058289A1 (en) | A method of preparing intranasal dry powders inhalant of calcitonin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14871728 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15105553 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2937049 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2014871728 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014871728 Country of ref document: EP |